Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.72 |
| ▸ | GPR174 | Q9BXC1 | 8/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320231 | 0.90 | ALDH1A1 (0.57) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL3312550 | 0.88 | ALDH1A1 (0.55) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL3317049 | 0.87 | MAPT (0.79) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL521504 | 0.86 | MAPT (0.59) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL31739514 | 0.84 | MAPT (0.67) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL3312015 | 0.84 | LMNA (0.64) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL30020102 | 0.84 | MAPT (0.69) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL3317301 | 0.83 | MAPT (0.81) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 | |
| SCHEMBL22621220 | 0.82 | GPR174 (1.00) | MAPTALDH1A1GPR174SMN1; SMN2CYP1A2 | |
| SCHEMBL30965513 | 0.82 | MAPT (0.67) | MAPTALDH1A1GPR174SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | ASTRAZENECA AB | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105655-A1 | NOVEL COMPOUNDS 515 | TYMS, ABCG2, UMPS | MAPT 2130/4885ALDH1A1 649/4885GPR174 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.